Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05347407 · ClinicalTrials.gov registry record

Parkinson's Disease Biomarkers in Nerve Cells in the Gut

A clinical trial of Parkinson Disease, sponsored by Weill Medical College of Cornell University.

Recruiting
Registry status
60
Enrollment target
1
Study location

NCT05347407 is a study of Parkinson Disease that is actively recruiting participants, run by Weill Medical College of Cornell University. The registered enrollment target is 60 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05347407, a study of Parkinson Disease, is actively recruiting participants, sponsored by Weill Medical College of Cornell University.

RECRUITING
Registry status
60 participants
Enrollment target
1
Study location

Study Summary

Parkinson's disease affects all the nerve cells in the body, including the ones in the gut. The gut contains its own nervous system, the enteric nervous system, and can be thought of as a "second brain". This second brain can reflect what is going on in the actual brain. This study is being done to look for biomarkers, or early indicators of developing Parkinson's disease, in the microbiome and in the gut tissue taken during routine screening colonoscopy. People aged 45 and over who are due for their routine screening colonoscopy are eligible to participate.

Conditions Studied

Interventions

  • PROCEDURE Colonoscopy

Study Locations (1)

New York

  • Weill Cornell Medicine - New York

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2020-12-30
Est. Completion 2026-06-01

What the Registry Record Tells You About NCT05347407

The ClinicalTrials.gov registry entry for NCT05347407 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which Colonoscopy is the first listed.

NCT05347407 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT05347407 about?

NCT05347407 is a clinical study titled "Parkinson's Disease Biomarkers in Nerve Cells in the Gut". Parkinson's disease affects all the nerve cells in the body, including the ones in the gut. The gut contains its own nervous system, the enteric nervous system, and can be thought of as a "second brain". This second brain can reflect what is going on in the actual brain. This study is being done to ...

What is the current status of trial NCT05347407?

This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2020-12-30. Estimated completion is 2026-06-01.

What conditions does trial NCT05347407 study?

This clinical trial studies the following conditions: Parkinson Disease.

What interventions are being tested in trial NCT05347407?

The interventions under investigation include: Colonoscopy (PROCEDURE).

Who is sponsoring clinical trial NCT05347407?

This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05347407 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Parkinson Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.